Journal of Experimental Medicine

3T Biosciences Expands Leadership Team With Bryan Irving, Ph.D., as Chief Scientific Officer to Progress Tumor-specific Therapies to Clinic

Retrieved on: 
Wednesday, October 25, 2023
Knowledge, CAR, PD-L1, UCSF, CSO, IND, Autoimmunity, Therapy, Culture, TCR, Lightspeed Venture Partners, Investigational New Drug, University of California, CTA, Acquisition, Immunity, Research, Journal of Experimental Medicine, Harvard University, Inflammation, Multimedia, R, Journal, Cancer immunology, Cell, Nature Communications, Immune system, Amgen, Drug discovery, Cancer, Microbiology, Canadian Aviation Regulations, Medical research, Immunotherapy, University, Roche, Sanofi, Genentech, Safety, Patient, Doctor of Philosophy, Coronavirus Scientific Advisory Board, Management, Vaccine, Pharmaceutical industry, Science

SOUTH SAN FRANCISCO, Calif., Oct. 25, 2023 /PRNewswire/ -- 3T Biosciences ("3T"), an immunotherapy company changing the future of treatment for solid tumors and other immune-mediated diseases, today announced the appointment of Bryan Irving, Ph.D., as chief scientific officer (CSO). In this role, Dr. Irving will be responsible for the company's scientific strategy and direction and will chair 3T's Scientific Advisory Board.

Key Points: 
  • In this role, Dr. Irving will be responsible for the company's scientific strategy and direction and will chair 3T's Scientific Advisory Board.
  • His work has focused primarily on exploring ways to modulate T-cell activity for therapeutic benefit in both oncology and autoimmune settings.
  • "3T shares my passion for innovation and has a culture of rigor and dedication to advancing novel therapies.
  • 3T Biosciences is an immunotherapy company focused on discovering and developing next-generation therapies with curative potential based on its immune-response-guided target discovery approach.

The Inner Circle Acknowledges, Ian A. Wilson as a Distinguished Healthcare Professional for his contributions to the Biomedical Research and Infectious Disease Fields

Retrieved on: 
Tuesday, September 5, 2023
Faculty, University of Oxford, National academy, Scripps Research, Society, University, TSRI, Structure, Therapy, Education, Vaccination, Academia Sinica, Journal of Experimental Medicine, SARS-CoV-2, Infection, Biomedical Research, American Academy, Royal, Research, Multimedia, Antibody, Inner circle, Biology, American Crystallographic Association, Molecular biology, British Society for Immunology, Publication, Newcomb Cleveland Prize, Medical research, Laboratory, Journal, Structural biology, University of Edinburgh, Harvard Society of Fellows, AAAS, HIV, Royal Society, Journal of Molecular Biology, Corpus Christi College, Computational biology, Nursing, Vaccine, Science, Biochemistry, Immunology

JOLLA, Calif., Sept. 5, 2023 /PRNewswire/ -- Prominently featured in The Inner Circle, Ian A. Wilson is acknowledged as a Distinguished Healthcare Professional for his contributions to the Biomedical Research and Infectious Disease Fields.

Key Points: 
  • JOLLA, Calif., Sept. 5, 2023 /PRNewswire/ -- Prominently featured in The Inner Circle, Ian A. Wilson is acknowledged as a Distinguished Healthcare Professional for his contributions to the Biomedical Research and Infectious Disease Fields.
  • Dr. Wilson pursued higher education at the prestigious University of Edinburgh in Scotland in 1971 where he earned a Bachelor of Science degree in Biochemistry.
  • In this post, he directed a laboratory involved in biomedical research on infectious diseases.
  • He currently serves as a Professor at Scripps Research (formerly The Scripps Research Institute or TSRI) in La Jolla, California.

Artiva Biotherapeutics Appoints Dr. Thorsten Graef as Chief Medical Officer

Retrieved on: 
Monday, June 6, 2022
Research, Clinical Trials, Stem Cells, Biotechnology, Health, Pharmaceutical, Other Science, Science, Oncology, GC, ADCC, Northwest Biotherapeutics, Research, Journal, Stanford University School of Medicine, Hematology, NK, CEO, PNAS, Investment, Medical research, Breast, Lymphoma, Journal of Experimental Medicine, Patient, Doctor of Philosophy, AbbVie, Lymphoid leukemia, Acquisition, Bladder cancer, MD, Clinical trial, Industry, Rituximab, Teaching hospital, Blood, Merck, Drug development, Internal medicine, Cancer, Merck & Co., NEJM, Pharmaceutical industry, Lancet, Pharmacyclics

Artiva Biotherapeutics, Inc. , an oncology company whose mission is to deliver highly effective, off-the-shelf allogeneic natural killer (NK) cell therapies that are safe and accessible to cancer patients, today announced the appointment of Thorsten Graef, M.D., Ph.D., as Chief Medical Officer.

Key Points: 
  • Artiva Biotherapeutics, Inc. , an oncology company whose mission is to deliver highly effective, off-the-shelf allogeneic natural killer (NK) cell therapies that are safe and accessible to cancer patients, today announced the appointment of Thorsten Graef, M.D., Ph.D., as Chief Medical Officer.
  • I was impressed by Artivas Manufacturing-First approach and pragmatic development program choices, stated Dr. Graef.
  • Most recently, Dr. Graef served as Chief Medical Officer at Acepodia USA, with responsibility for all of the companys research and clinical development activities.
  • Prior to Pharmacyclics, Dr. Graef served as medical director of Merck Research Lab, Oncology at Merck & Co., Inc.